Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
Gordon J. Freeman(Dana-Farber Cancer Institute), Lee M. Nadler(Dana-Farber Cancer Institute), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Vincent A. Restivo(Dana-Farber Cancer Institute), John G. Gribben(Queen Mary University of London), Lisa A. Lombard(Dana-Farber Cancer Institute), Gary S. Gray(Repligen (United States)), Judy W. Ng(Dana-Farber Cancer Institute)
Cited by 914
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k